Business Context and Reporting Period
Ocular Therapeutix, Inc. (OCUL) filed this Form 8-K on October 7, 2020, to provide a business update regarding its preliminary operational and financial results for the third quarter ended September 30, 2020. The company is currently finalizing its official financial closing procedures.
Key Financial Metrics
The filing provides estimated net product revenue figures for the third quarter of 2020, which are preliminary and unaudited. No data regarding profit, cash flow, margins, debt, or liquidity is provided in this specific filing.
- Estimated Q3 2020 Total Net Product Revenue: $5.8 million to $5.9 million.
- Q3 2020 DEXTENZA Revenue: Estimated between $5.3 million and $5.4 million.
- Q3 2020 ReSure Sealant Revenue: Estimated at approximately $0.5 million.
- Q3 2020 In-Market Unit Sales: 2,221 units (July), 2,920 units (August), and an estimated 4,812 units (September).
Material Changes Versus Prior Period
The company reported significant growth in revenue compared to the second quarter ended June 30, 2020.
- Total Revenue Growth: Q3 estimated revenue ($5.8M–$5.9M) represents a substantial increase from Q2 revenue of approximately $1.6 million.
- DEXTENZA Growth: Revenue increased from approximately $1.4 million in Q2 to an estimated $5.3 million–$5.4 million in Q3.
- ReSure Growth: Revenue increased from approximately $0.2 million in Q2 to an estimated $0.5 million in Q3.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future strategy, or specific risk factors beyond the standard disclaimer regarding the preliminary nature of the data.
Unusual Items and Disclaimers: The revenue figures are based on management estimates and preliminary information. The company's independent registered public accounting firm has not audited or reviewed these figures and does not express an opinion on them. The data is subject to change upon completion of the financial closing procedures.
Investor Verification Checklist
- Verify the final audited revenue figures in the upcoming Form 10-Q for the quarter ended September 30, 2020.
- Confirm the final unit sales volume for September 2020, as the current figure is an estimate.
- Review the full press release (Exhibit 99.1) for any additional operational details not summarized in the 8-K text.
- Monitor subsequent filings for updates on gross margins and operating expenses, which are not disclosed in this report.